Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.62 |
| ▸ | MPL | P40238 | 2/20 | 0.62 |
| ▸ | ATP4A | P20648 | 2/20 | 0.59 |
| ▸ | ATP4B | P51164 | 2/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.52 |
| ▸ | RELA | Q04206 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30123146 | 1.00 | HSD17B10 (0.62) | HSD17B10MPLATP4AATP4BCYP19A1 | |
| Bromide SCHEMBL1915171 | 0.98 | HSD17B10 (0.61) | HSD17B10MPLATP4AATP4BCYP19A1 | |
| SCHEMBL29654229 | 0.92 | CYP19A1 (0.63) | HSD17B10MPLATP4AATP4BCYP19A1 | |
| SCHEMBL14315464 | 0.87 | CYP19A1 (0.58) | HSD17B10MPLATP4AATP4BCYP19A1 | |
| SCHEMBL474398 | 0.85 | MPL (0.54) | HSD17B10MPLATP4AATP4BCYP19A1 | |
| SCHEMBL1801817 | 0.82 | MPL (0.63) | HSD17B10MPLATP4AATP4BALDH1A1 | |
| SCHEMBL3772673 | 0.81 | CYP19A1 (0.58) | HSD17B10ATP4AATP4BCYP19A1ALDH1A1 | |
| SCHEMBL30378574 | 0.81 | CYP19A1 (0.58) | HSD17B10ATP4AATP4BCYP19A1ALDH1A1 | |
| SCHEMBL4367505 | 0.80 | HSD17B10 (0.67) | HSD17B10MPLALDH1A1KDM4ERAB9A | |
| SCHEMBL30929654 | 0.80 | ATP4A (0.51) | ATP4AATP4BCYP19A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098895-B1 | METHOD FOR PREPARING LINTITRIPT POTASSIUM SALT | SANOFI SYNTHELABO (FR) | 2002-06-05 | — | — | EP | claimed |
| US-6365748-B1 | BY TREATING 2-((4-(2-CHLOROPHENYL)-2-THIAZOLYL)CARBAMOYL) INDOLE-1-ACETIC ACID OR ITS ESTERS WITH POTASSIUM CARBONATE IN A TWO PHASE SOLVENT SYSTEM,OF A MIXTURE OF WATER AND A SLIGHTLY IMMISCIBIBLE SOLVENT; INJECTIBLE CHOLECYSTOKININ | SANDOFI-SYNTHELABO (FR) | 2002-04-02 | — | — | US | claimed |
| CN-115850202-B | Small molecule inhibitor of frizzled receptor 7 and preparation method and application thereof | 上海科技大学 | 2024-06-25 | — | — | CN | disclosed |
| US-20230212131-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212131-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212131-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-07-06 | — | — | US | disclosed |
| EP-4161921-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | Anima Biotech Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| CN-115916776-A | Collagen 1 translation inhibitors and methods of use thereof | 艾尼莫生物科技公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115850202-A | Small molecule inhibitor of frizzled receptor 7 and preparation method and application thereof | 上海科技大学 | 2023-03-28 | — | — | CN | disclosed |
| CN-115466229-A | P-acylamino benzenesulfonyl compound and application thereof | 上海中医药大学 | 2022-12-13 | — | — | CN | disclosed |
| US-11345714-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20070265265-A1 | N-(5-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. | 2007-11-15 | — | — | US | disclosed |
| WO-2007070600-A2 | N-(5-MEMBERED HETEROAROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| US-7132436-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2006-11-07 | — | — | US | disclosed |
| US-20030166689-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | CLARIO TECH LIMITED (GB) | 2003-09-04 | — | — | US | disclosed |
| CN-1437588-A | 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors | BIOVITRUM AB (SE) | 2003-08-20 | — | — | CN | disclosed |
| EP-1098895-B1 | METHOD FOR PREPARING LINTITRIPT POTASSIUM SALT | SANOFI SYNTHELABO (FR) | 2002-06-05 | — | — | EP | disclosed |
| US-6365748-B1 | BY TREATING 2-((4-(2-CHLOROPHENYL)-2-THIAZOLYL)CARBAMOYL) INDOLE-1-ACETIC ACID OR ITS ESTERS WITH POTASSIUM CARBONATE IN A TWO PHASE SOLVENT SYSTEM,OF A MIXTURE OF WATER AND A SLIGHTLY IMMISCIBIBLE SOLVENT; INJECTIBLE CHOLECYSTOKININ | SANDOFI-SYNTHELABO (FR) | 2002-04-02 | — | — | US | disclosed |
| EP-1098895-A1 | METHOD FOR PREPARING LINTITRIPT POTASSIUM SALT | SANOFI-SYNTHELABO (FR) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000005233-A1 | METHOD FOR PREPARING LINTITRIPT POTASSIUM SALT | SANOFI-SYNTHELABO (FR) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345714-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | HSD17B10 4503/4885MPL 4371/4885ATP4A 2678/4885 |
| US-20230212131-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | COL1A1, COL2A1, COL14A1 | HSD17B10 3757/4885MPL 3649/4885ATP4A 2573/4885 |
| US-20030166689-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | HSD17B10 22/4885MPL 4255/4885ATP4A 1305/4885 |
| US-20070265265-A1 | N-(5-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | ZC3HAV1, ZC3HAV1L, HAVCR2 | HSD17B10 4112/4885MPL 3886/4885ATP4A 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.